United States-based GW Pharmaceuticals in collaboration with its United States subsidiary Greenwich Biosciences has introduced EPIDIOLEX (cannabidiol) oral solution CV in the United States, it was reported on Friday.
The product is intended for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older. It was approved by the US Food and Drug Administration (FDA) and is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol, a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.
The firm has launched a comprehensive patient support program called EPIDIOLEX Engage, which is designed to help patients who have been prescribed EPIDIOLEX gain access to therapy. The program provides patient/caregiver-focused education and resources to help reduce out-of-pocket costs or provide product at no cost for eligible patients.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial